{
    "Clinical Trial ID": "NCT00432562",
    "Intervention": [
        "INTERVENTION 1: ",
        "  ANX-530",
        "[Not Specified]",
        "INTERVENTION 2: ",
        "  Navelbine",
        "[Not Specified]"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Age > 18 years.",
        "  Advanced cancer potentially sensitive to vinorelbine:",
        "  Breast cancer.",
        "  Stage 3 or 4 non-small cell lung cancer.",
        "  Non-Hodgkins lymphoma.",
        "  Cancer of other histologic type, sensitive to vinca alkaloids.",
        "  Rare tumor type with no standard treatment, for which single agent vinorelbine is appropriate therapy.",
        "  Failure of standard treatment(s) of the tumor.",
        "  Life expectancy of at least three months.",
        "  ECOG performance level 0-2 or Karnofsky score 100-70.",
        "  Hematological and serum chemistry results with defined ranges.",
        "  Willingness and ability to provide written informed consent.",
        "Exclusion Criteria:",
        "  Pregnancy or lactation. In a woman of childbearing potential, a positive pregnancy test result, no pregnancy test result, or no use of reliable contraception, at baseline. A postmenopausal woman will be considered to be of childbearing potential until there has been amenorrhea for at least 12 consecutive months.",
        "  Previous treatment with vinorelbine or mitomycin.",
        "  Any history suggesting or demonstrating resistance to, lack of response to, or intolerance of any prior vinca alkaloid treatment.",
        "  Active infection.",
        "  Prior anticancer therapy completed within four weeks prior to the first day of study treatment.",
        "  Failure to have recovered from any toxicity of previous cancer treatment (patients with alopecia will not be excluded).",
        "  Participation in another experimental drug study within four weeks prior to the first day of study treatment.",
        "  Requirement for any concomitant chemotherapeutic agent other than the study medication.",
        "  Any investigator judgment that the individual would not be an appropriate study subject."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Time to Reach Maximum Observed Plasma Concentration (Tmax)",
        "  [Not Specified]",
        "  Time frame: 0-144 hours post dose",
        "Results 1: ",
        "  Arm/Group Title: ANX-530",
        "  Arm/Group Description: [Not Specified]",
        "  Overall Number of Participants Analyzed: 31",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: hours  0.35         (0.13)",
        "Results 2: ",
        "  Arm/Group Title: Navelbine",
        "  Arm/Group Description: [Not Specified]",
        "  Overall Number of Participants Analyzed: 31",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: hours  0.34         (0.08)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 5/16 (31.25%)",
        "  ANAEMIA 1/16 (6.25%)",
        "  LEUKOPENIA 1/16 (6.25%)",
        "  NEUTROPENIA 3/16 (18.75%)",
        "  THROMBOCYTOPENIA 1/16 (6.25%)",
        "  FEBRILE INFECTION 1/16 (6.25%)",
        "  GENITAL INFECTION FEMALE 1/16 (6.25%)",
        "  PNEUMONIA 1/16 (6.25%)",
        "  CANCER PAIN 1/16 (6.25%)",
        "  STUPOR 1/16 (6.25%)",
        "  COMA 1/16 (6.25%)",
        "  RESPIRATORY FAILURE 1/16 (6.25%)",
        "Adverse Events 2:",
        "  Total: 1/15 (6.67%)",
        "  ANAEMIA 0/15 (0.00%)",
        "  LEUKOPENIA 0/15 (0.00%)",
        "  NEUTROPENIA 0/15 (0.00%)",
        "  THROMBOCYTOPENIA 0/15 (0.00%)",
        "  FEBRILE INFECTION 1/15 (6.67%)",
        "  GENITAL INFECTION FEMALE 0/15 (0.00%)",
        "  PNEUMONIA 0/15 (0.00%)",
        "  CANCER PAIN 0/15 (0.00%)",
        "  STUPOR 0/15 (0.00%)",
        "  COMA 0/15 (0.00%)",
        "  RESPIRATORY FAILURE 0/15 (0.00%)"
    ]
}